Compare PMTS & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PMTS | SWKH |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Diversified Financial Services |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.1M | 205.9M |
| IPO Year | 2015 | 1999 |
| Metric | PMTS | SWKH |
|---|---|---|
| Price | $13.73 | $17.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $32.00 | $18.00 |
| AVG Volume (30 Days) | ★ 42.3K | 12.3K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | 1.20 | ★ 1.85 |
| Revenue | ★ $515,576,000.00 | $40,149,000.00 |
| Revenue This Year | $13.70 | $52.93 |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | $11.53 | ★ $9.45 |
| Revenue Growth | 12.48 | ★ 62.38 |
| 52 Week Low | $11.64 | $13.17 |
| 52 Week High | $34.25 | $20.49 |
| Indicator | PMTS | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 56.81 |
| Support Level | $13.61 | $17.11 |
| Resistance Level | $14.83 | $17.50 |
| Average True Range (ATR) | 0.56 | 0.22 |
| MACD | -0.24 | -0.01 |
| Stochastic Oscillator | 4.26 | 74.00 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.